BLUETTI to Release AC180, Making Another Breakthrough in Portable Power Station Area
Spring camping has gradually become popular in recent years, providing a precious chance for people to get rid of the hustle and bustle of urban life and have close contact with nature. However, most of their trips experienced mobile power shortages out there.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230421005196/en/
(Photo: Business Wire)
BLUETTI, a market leader in the energy storage industry, is about to unveil a brand-new model. As a successor of the previous portable stations such as EB150 and EB240, AC180 is designed with a bunch of improvements that kit it up a notch, making it a well-deserved portable power station for emergency backup, sudden blackouts, excursions, and more.
Explore Outdoors with Great Capacity
To help elevate the off-grid lifestyle, BLUETTI equips AC180 with a 1800W constant output power and 1.152Wh capacity, covering almost all power demands of essentials at home or in the wild. Furthermore, AC 180 also comes with a Power Lifting Mode of 2.700W output to effortlessly run high-powered devices like kettles, hair dryers, microwaves, etc.
Besides, AC180 is updated with a 1,7-inch LCD display and bigger font size to make the power consumption and troubleshooting status more visualized and clearly.
Travel with Grab-and-go Power
Pack lighter, travel further. In view of portability, AC180 is ultra compact for effortless transportation as it measures 340mmｘ247mmｘ317mm (H x W x H) and weighs only 35kg. It does not occupy too much space of the truck on the way to the next campsite.
Recharge with High Speed
For outdoor enthusiasts looking for backup power for their camping or RV trips on the road, AC180 is sure to exceed their expectations. Even exploring off the beaten track far from the main grid, the reliable power source is always on call as AC180 supports up to 1.440W Turbo Charging, 0-80% SOC only takes about 45mins! Get it charged before packing up for the getaway, a large amount of power is ready to hit the road when you are.
Live with Uninterrupted Power Supply
Given the UPS system, there’s no need to worry about losing data or hardware damage in the event of a power outage since AC180 can automatically detect the blackout the moment it occurs and seamlessly switch over in 20ms that no one can even be aware of.
Constant Power with Peace of Mind
Keeping high security and longevity in mind, BLUETTI adopts safe and durable LiFePO4 battery cells and guarantees a worry-free warranty for as long as 5 years, which really sets it apart from most competitors throughout the market.
Remotely monitoring AC180 in real time is a no-brainer thanks to the intelligent BLUETTI APP. Now setting up working modes, checking the system conditions, and OTA updates can be done solely with fingertips.
“We’re dedicated to more innovations that’s a right fit for the increasing market demand. Our R&D team once envisioned a power station integrated with portability, capability, and cost performance, and now we’ve made it come true. AC180 has everything users could possibly need without costing an arm and a leg,” said James Ray, the marketing director of BLUETTI.
Availability
Though the debut price is not finally decided yet, it’s believed to be the most affordable power station that worth the wait.
About BLUETTI
From the very beginning, BLUETTI has tried to stay true to a sustainable future through green energy storage solutions for both indoor and outdoor use while delivering an exceptional eco-friendly experience for our homes and our world. That's why BLUETTI makes its presence in 70+ countries and is trusted by millions of customers across the globe. For more information, please visit BLUETTI online at https://www.bluettipower.eu/ or follow BLUETTI on:
YouTube: https://www.youtube.com/c/bluettiofficial
Facebook: https://www.facebook.com/bluettipower.eu/
Twitter: https://twitter.com/bluetti_inc
Instagram: https://www.instagram.com/bluetti_europe/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230421005196/en/
Contact information
jacinda@bluetti.com
130 4085 7737
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
Daiichi Sankyo and GENESIS Pharma Enter Exclusive Agreement for VANFLYTA ® Commercialization in Central and Eastern Europe7.1.2026 09:30:00 EET | Press release
Daiichi Sankyo (TSE: 4568) and GENESIS Pharma have entered into an exclusive license and supply agreement for the distribution and commercialization of VANFLYTA® (quizartinib) in 13 markets across Central and Eastern Europe for the treatment of adult patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML). Under the terms of the agreement, Daiichi Sankyo will be responsible for the manufacturing and supply of VANFLYTA while GENESIS Pharma will lead medical affairs, market access and commercialization efforts in Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Hungary, Latvia, Lithuania, Malta, Poland, Romania, Slovakia and Slovenia. Financial terms of the agreement are not being disclosed. VANFLYTA was approved in the EU in November 2023 for the treatment of adult patients with newly diagnosed FLT3-ITD positive AML in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as maintenance monotherap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom